Tenax Therapeutics, Inc.
TENX
Positions held
Your positionsTENX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $69.61M | Enterprise value | -$11.43M | Trailing P/E | — | Forward P/E | -1.24 |
| PEG | 1.44 | Price / book | 0.85 | Beta | 0.92 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -59.8% | ROA | -37.7% | Debt / equity | — |
| Current ratio | 15.07 | Free cash flow | -$24.05M | Analyst recommendation | none | Mean target | $12.56 |
| 52w high | $19.40 | 52w low | $1.31 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$17.8M | -$15.7M | -$15.5M | -$15.8M | -$10.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.8M | -$16.6M | -$16.4M | -$16.8M | -$11.8M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$52.6M | -$17.6M | -$7.7M | -$11.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$56.4M | -$19.5M | -$8.2M | -$11.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
2026-08-31 · Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
2026-08-31 · Guggenheim Downgrades Tenax Therapeutics to Neutral From Buy
2026-08-11 · Chardan Downgrades Tenax Therapeutics to Neutral From Buy, Adjusts Price Target to $5 From $27
2026-08-11 · Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39
2026-08-11 · Tenax Therapeutics’ stock crashes on Phase III trial failure
2026-08-11 · Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
2026-08-10 · Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
2026-08-10 · Tenax, Sionna Shares Sink After Trial Failures
2026-08-10 · BC-Most Active Stocks
Price (daily)
Full chart · RSI · MACD · patterns